PTJ
AKYA

Paul Tudor Jones’s Akoya BioSciences AKYA Stock Holding History

Paul Tudor Jones’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,444
Closed -$279K – 2414
2021
Q2 		$279K Buy
+14,444
New +$298K 0.01% 1375

Other funds holding AKYA

BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
HEC
Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Paul Tudor Jones's AKYA Position: Q3 2021 in Review

Paul Tudor Jones sold out of Akoya BioSciences (AKYA) in Q3 2021, closing a stake of 14,444 shares — an estimated $279K sold.

Paul Tudor Jones first reported a position in AKYA in Q2 2021 and held it in 1 quarter. The position peaked at $279K in Q2 2021. 47 funds tracked by Wall St. Rank hold AKYA as of Q3 2021.

  • Paul Tudor Jones reported no remaining Akoya BioSciences position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 14,444 Akoya BioSciences shares in Q3 2021, an estimated $279K.
  • Paul Tudor Jones first reported a position in Akoya BioSciences in Q2 2021 and held it in 1 quarter.
  • Paul Tudor Jones's Akoya BioSciences position peaked at $279K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.